157 related articles for article (PubMed ID: 37318381)
1. Circulating cell-free DNA sequencing for early detection of lung cancer.
Xue R; Yang L; Yang M; Xue F; Li L; Liu M; Ren Y; Qi Y; Zhao J
Expert Rev Mol Diagn; 2023; 23(7):589-606. PubMed ID: 37318381
[TBL] [Abstract][Full Text] [Related]
2. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
[TBL] [Abstract][Full Text] [Related]
3. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
4. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
5. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection.
Su S; Xuan Y; Fan X; Bao H; Tang H; Lv X; Ren W; Chen F; Shao Y; Wang T; Wang L
Genomics; 2023 Jul; 115(4):110662. PubMed ID: 37270068
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA methylation in the clinical management of lung cancer.
Ezegbogu M; Wilkinson E; Reid G; Rodger EJ; Brockway B; Russell-Camp T; Kumar R; Chatterjee A
Trends Mol Med; 2024 May; 30(5):499-515. PubMed ID: 38582623
[TBL] [Abstract][Full Text] [Related]
7. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.
van der Pol Y; Tantyo NA; Evander N; Hentschel AE; Wever BM; Ramaker J; Bootsma S; Fransen MF; Lenos KJ; Vermeulen L; Schneiders FL; Bahce I; Nieuwenhuijzen JA; Steenbergen RD; Pegtel DM; Moldovan N; Mouliere F
EMBO Mol Med; 2023 Dec; 15(12):e17282. PubMed ID: 37942753
[TBL] [Abstract][Full Text] [Related]
8. Analysis of genome-wide in cell free DNA methylation: progress and prospect.
Liu Z; Wang Z; Jia E; Ouyang T; Pan M; Lu J; Ge Q; Bai Y
Analyst; 2019 Oct; 144(20):5912-5922. PubMed ID: 31436778
[TBL] [Abstract][Full Text] [Related]
9. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
[TBL] [Abstract][Full Text] [Related]
10. Circulating cell-free DNA-based methylation pattern in plasma for early diagnosis of esophagus cancer.
Wang R; Yang Y; Lu T; Cui Y; Li B; Liu X
PeerJ; 2024; 12():e16802. PubMed ID: 38313016
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract][Full Text] [Related]
14. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
16. At the dawn: cell-free DNA fragmentomics and gene regulation.
Liu Y
Br J Cancer; 2022 Feb; 126(3):379-390. PubMed ID: 34815523
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
18. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization.
Nguyen VTC; Nguyen TH; Doan NNT; Pham TMQ; Nguyen GTH; Nguyen TD; Tran TTT; Vo DL; Phan TH; Jasmine TX; Nguyen VC; Nguyen HT; Nguyen TV; Nguyen THH; Huynh LAK; Tran TH; Dang QT; Doan TN; Tran AM; Nguyen VH; Nguyen VTA; Ho LMQ; Tran QD; Pham TTT; Ho TD; Nguyen BT; Nguyen TNV; Nguyen TD; Phu DTB; Phan BHH; Vo TL; Nai THT; Tran TT; Truong MH; Tran NC; Le TK; Tran THT; Duong ML; Bach HPT; Kim VV; Pham TA; Tran DH; Le TNA; Pham TVN; Le MT; Vo DH; Tran TMT; Nguyen MN; Van TTV; Nguyen AN; Tran TT; Tran VU; Le MP; Do TT; Phan TV; Nguyen HL; Nguyen DS; Cao VT; Do TT; Truong DK; Tang HS; Giang H; Nguyen HN; Phan MD; Tran LS
Elife; 2023 Oct; 12():. PubMed ID: 37819044
[TBL] [Abstract][Full Text] [Related]
19. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
20. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
